Can Fite BioPharma Ltd (CANF)

[midastouch017]

Can-Fite soars 45% on positive namodenoson data in liver cancer

Feb. 22, 2021 7:41 AM ETCan-Fite BioPharma Ltd. (CANF)
By: Mamta Mayani, SA News Editor

Can-Fite BioPharma (NYSEMKT:CANF) gains 45% premarket in reaction to the new data from the Phase II advanced liver cancer study including overall survival of nearly 4 years in two patients under namodenoson treatment.

Additional findings show disappearance of ascites, normal liver function and good quality of life.

Stable disease has been recorded with retreating peritoneal carcinomatosis.
Namodenoson demonstrates a good safety profile and is well tolerated with no severe adverse events reported.

Recently, the Company concluded End-of-Phase II meetings with the FDA and EMA. Both agencies agreed with Can-Fite’s proposed Phase III trial design of Namodenoson in hepatocellular carcinoma, with underlying Child Pugh B7 cirrhosis to support a NDA submission and approval.